pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Pedmark
drug
save

sodium thiosulfate

Marketedupdated 3mo ago
by $REGN REGENERON PHARMACEUTICALS, INC.
Approved
community read0 votes

🐶 often sniffed alongside

top 4
  • tagOncology7 co-mentions · 1 sources
  • company$FENCFENNEC PHARMACEUTICALS INC.1 co-mentions · 1 sources
  • tagPulmonology1 co-mentions · 1 sources
  • tagNSCLC1 co-mentions · 1 sources

all catalysts(1)

phase 1 2 initiation · 1
Apr 30, 2026
phase 1 2 initiation
$FENC11.72-2.82%
4mo ago
Fennec Pharmaceuticals Inc — sodium thiosulfate (Phase I/II Trial Initiation)
sodium thiosulfate
→

Trials studying sodium thiosulfate

  • phase3Better Evidence and Translation for Calciphylaxisrecruitingn=350
  • phase3Double-blind Trial of Sodium Thiosulfate for the Treatment of Pain Associated With Calcific Uremic Arteriolopathywithdrawn

Patent cliff

source: FDA Orange Book
first barrier falls
Sep 20, 2029
~3.1 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (12)

  • Jul 1, 2039formulationUS 11291728
  • Jul 1, 2039formulationUS 11510984
  • Jul 1, 2039formulationUS 11617793
  • Jul 1, 2039method-of-use (U-3898)US 11964018
  • Jul 1, 2039method-of-use (U-3948)US 11992530
  • Jul 1, 2039method-of-use (U-3952)US 11998604
  • Mar 29, 2031compositionUS 84969734.6y
  • Jul 7, 2030formulationUS 104796863.9y
  • Jul 7, 2030compositionUS 93457243.9y
  • Jul 7, 2030compositionUS 95859123.9y
  • Feb 10, 2030compositionUS 117533013.5y
  • Feb 10, 2030formulationUS 123048133.5y

FDA exclusivities (1)

  • Sep 20, 2029ODE-384Orphan Drug (7y)3.1y

News(0)

no news has mentioned this drug yet

brand
Pedmark
generic
sodium thiosulfate
indication
Hearing Disorders
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?